Table 3.

Rivaroxaban plus aspirin versus control outcomes

		Rivaroxaban plus aspirin group (n=1063)	Control group (n=1056)	Hazard ratio (95% CI)	p value
Major thrombosis, high-flow oxygen, ventilation, or death*		281 (26·4%)	300 (28·4%)	0·92 (0·78–1·09)	0·32
Any thrombosis, high-flow oxygen, ventilation, or respiratory death†		269 (25·3%)	280 (26·5%)	0·95 (0·80–1·12)	0·53
	Major thrombosis‡	10 (0·9%)	18 (1·7%)	0·56 (0·26–1·21)	0·14
	Any thrombosis§	17 (1·6%)	20 (1·9%)	0·85 (0·45–1·63)	0·63
	Venous thromboembolism	13 (1·2%)	10 (0·9%)	1·31 (0·58–3·00)	0·52
	High-flow oxygen or ventilation	191 (18·0%)	210 (19·9%)	0·89 (0·73–1·09)	0·27
	Death	193 (18·2%)	186 (17·6%)	1·05 (0·86–1·28)	0·66
	Respiratory death	145 (13·6%)	138 (13·1%)	1·06 (0·84–1·34)	0·61

Data are n (%) unless stated otherwise.

^*Primary outcome.

^†Secondary outcome.

^‡Includes stroke, myocardial infarction, acute limb ischaemia, and pulmonary embolism.

^§Includes major thrombosis plus deep vein thrombosis.